DISCLAIMER

DISCLAIMER: The author is not a registered stockbroker nor a registered advisor and does not give investment advice. His comments are an expression of opinion only and should not be construed in any manner whatsoever as recommendations to buy or sell a stock, option, future, bond, commodity, index or any other financial instrument at any time. While he believes his statements to be true, they always depend on the reliability of his own credible sources. The author recommends that you consult with a qualified investment advisor, one licensed by appropriate regulatory agencies in your legal jurisdiction, before making any investment decisions, and that you confirm the facts on your own before making important investment commitments.

Thursday, January 14, 2010

GlaxoSmithKline plc (GSK) Sees Little Threat To Advair From Generic Competition

GlaxoSmithKline plc (ADR) sees little threat to its top selling drug Advair from generic competition, according to GlaxoSmithKline Chief Executive Andrew Witty.

Speaking at the JPMorgan Healthcare Conference, Mr. Witty said that it is very difficult to make a generic and that he has not heard any thing this week that would make him change his mind. Advair could encounter competition in the key US market in 2011 but the drug is delivered by an inhaler. This will complicate matters for generic producers.

It will also be difficult for generic producers to get approval for a generic version of Advair as a straightforward substitute. Mr. Witty also said that GlaxoSmithKline was in the process of producing generic versions of its drugs that will be losing patent protection.

Claim your Free Book "make Real Money On The Internet"

Posted by at
Labels: , , , , ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)